Androgen deprivation therapy through bilateral orchiectomy: Increased metabolic risks

Asian Journal of Andrology

Volumn 13, Issue 6, 2011, Pages 833-837

  Bo, Juan Jie ^a   Zhang, Chao ^a   Zhang, Lian Hua ^a   Liu, Ping ^a   Sha, Jian Jun ^a   Lv, Jian Wei ^a   Liu, Dong Ming ^a   Huang, Yi Ran ^a   Li, Zheng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

androgen deprivation therapy; bilateral orchiectomy; metabolic changes; metabolic syndrome; prostate cancer

Indexed keywords

CHOLESTEROL; FLUTAMIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; TESTOSTERONE; TRIACYLGLYCEROL;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER PATIENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORBIDITY; ORCHIECTOMY; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

AGED; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; FLUTAMIDE; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 80755167915     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.83     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Ye DW, Li CL. Epidemiological trends of prostate cancer: retrospect and prospect. Chin Oncol 2007; 17: 177-80.
3. Ries LA, Eisner MP, Kosary CL, Hankey BF, Miller BA et al. editors. SEER Cancer Statistics Review, 1975-2001. Bethesda, MD: National Cancer Institute; 2004. Available at: http://seer.cancer.gov/csr/1975-2001/
4. Kato I, Severson RK, Schwartz AG. Conditional median survival of patients with advanced carcinoma: surveillance, epidemiology, and end results data. Cancer 2001; 92: 2211-9.
5. Huggins C, Stevens RE Jr, Hodges CV. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209-23.
6. Barry MJ, Delorenzo MA, Walker-Corkery ES, Lucas FL, Wennberg DC. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int 2006; 98: 973-8. (Pubitemid 44536442)
7. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300. (Pubitemid 27318990)
8. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-8.
9. Payne H. Management of locally advanced prostate cancer. Asian J Androl 2009; 11: 81-7.
10. Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C et al. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 2009; 55: 62-75.
11. Schwandt A, Garcia JA. Complications of androgen deprivation therapy in prostate cancer. Curr Opin Urol 2009; 19: 322-6.
12. Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009; 115: 2388-99.
13. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-56. (Pubitemid 46630983)
14. Wadhwa VK, Weston R, Parr NJ. A large proportion of patients with prostate cancer undergoing androgen deprivation therapy continue to die from non-cancer causes in the PSA era. Br J Med Surg Urol 2009; 2: 191-6.
15. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-62. (Pubitemid 41338752)
16. Tadros NN, Garzotto M. Androgen deprivation therapy for prostate cancer: not so simple. Asian J Androl 2011; 13: 187-8.
17. Brown BW, Brauner C, Minnotte MC. Noncancer deaths in white adult cancer patients. J Natl Cancer Inst 1993; 85: 979-87. (Pubitemid 23177584)
18. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010; 102: 39-46.
19. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts Male Aging Study. Diabetes Care 2000; 23: 490-4. (Pubitemid 30185792)
20. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036-41. (Pubitemid 38579762)
21. Simon D, Charles MA, Nahoul K, Orssaud G, Kremski et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. J Clin Endocrinol Metab 1997; 82: 682-5. (Pubitemid 27068651)
22. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006; 295: 1288-99.
23. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305-08.
24. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who received androgen deprivation therapy. Cancer 2006; 106: 581-8. (Pubitemid 43157621)
25. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci 2003; 104: 195-201. (Pubitemid 36238052)
26. Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S. Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 2006; 18: 494-8. (Pubitemid 44330303)
27. Gade W, Schmit J, Collins M, Gade J. Beyond obesity: the diagnosis and pathophysiology of metabolic syndrome. Clin Lab Sci 2010; 23: 51-61.
28. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010; 121: 833-40.
29. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 3979-83. (Pubitemid 46630747)
30. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res 2009; 21: 1-8.
31. Allen NE, Appleby PN, Davey GK, Key TJ. Lifestyle and nutritional determinants of bioavailable androgens and related hormones in British men. Cancer Causes Control 2002; 13: 353-63. (Pubitemid 34553516)
32. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004; 63: 742-5. (Pubitemid 38479421)
33. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599-603. (Pubitemid 34158224)
34. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285, 2486-97.
35. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53. (Pubitemid 28319935)
36. Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 2008; 71: 318-22. (Pubitemid 351282338)
37. Smith MR, Lee H, McGovern F, Fallon MA, Goode M et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008; 112: 2188-94. (Pubitemid 351628628)
38. Limonta P, Montagnani MM, Moretti RM. LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs 2001; 10: 709-20. (Pubitemid 32288188)